Crinetics Pharmaceuticals, Inc. (CRNX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 1,031 | 361 | - | |
| Research and development | 80,301 | 76,240 | 61,905 | |
| Selling, general and administrative | 49,842 | 35,526 | 25,892 | |
| Total operating expenses | 130,143 | 111,766 | 87,797 | |
| Loss from operations | -129,112 | -111,405 | -87,797 | |
| Interest income | 13,455 | 14,834 | 11,006 | |
| Other income (expense), net | 20 | -203 | -37 | |
| Total other income, net | 13,475 | 14,631 | 10,969 | |
| Loss before equity method investment | 115,637 | 96,774 | 76,828 | |
| Loss on equity method investment | - | - | - | |
| Net loss | -115,637 | -96,774 | -76,828 | |
| Unrealized gain (loss) on investment securities | -347 | 1,033 | 2,228 | |
| Unrealized gain on foreign currency | -34 | 6 | - | |
| Total other comprehensive income (loss) | -381 | 1,039 | - | |
| Comprehensive loss | -116,018 | -95,735 | -74,600 | |
| Earnings per share, basic, total | -1.23 | -1.04 | -0.96 | |
| Earnings per share, diluted, total | -1.23 | -1.04 | -0.96 | |
| Weighted average number of shares outstanding, basic, total | 93,791,000 | 93,102,000 | 80,091,000 | |
| Weighted average number of shares outstanding, diluted, total | 93,791,000 | 93,102,000 | 80,091,000 | |